Drug Profile


Alternative Names: Clevelox; Cleviprex

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Antihypertensives; Dihydropyridines
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension; Perioperative hypertension

Most Recent Events

  • 21 Jun 2016 Chiesi USA and Chiesi Farmaceutici acquired multinational rights to clevidipine (Cleviprex®) from The Medicines Company
  • 24 Jun 2015 Launched for Perioperative hypertension in Austria, France, Germany, Luxembourg, Spain and Sweden (IV) before June 2015
  • 18 Dec 2014 Clevidipine licensed to SciClone Pharmaceuticals in China, excluding Hong Kong and Macau
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top